It's long been considered a disease for older people but research shows bowel cancer rates in young people are rising. And ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Black women experience advanced diagnoses 55% more often than white women and are more likely to die from the disease, the ...

In addition to late-stage diagnosis, this younger demographic is more likely to be diagnosed with aggressive forms of breast cancer such as triple-negative breast cancer and HER2-Positive breast ...

Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to ...

The number of women with late-stage, invasive breast cancer at the time of diagnosis increased significantly among U.S. women ...

THE INCIDENCE of late-stage breast cancer is increasing in the USA, with women of all age groups and ethnic backgrounds ...

"More late-stage disease means more breast cancer deaths," said Dr. Debra Monticciolo, co-author and an emeritus faculty member at Baylor Scott & White Medical Center in central Texas. This data ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...

Merck's combination also helped suppress viral replication in adults compared to other antiretroviral therapy in a separate open-label late-stage study. The company plans to file the data with ...

The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women have been hit the hardest, according to a new study published in the ...